Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refractory lymphomas or cert…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Burkitt Lymphoma
• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Mantle Cell Lymphoma
• Mycosis Fungoides Sezary Syndrome

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (rituximab)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of Washington | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-25